Furthermore, CD93 blocking effectively elevated the proportion of effector T cells in melanoma, making tumors more sensitive to anti-PD-1/PD-L immune checkpoints treatment (Sun et al. 2021b). The gene discussed is CD93; the disease is melanoma.